1 tame: An R package for identifying clusters of medication use

2 based on dose, timing and type of medication

- Anna Laksafoss1*, Jan Wohlfahrt2 , Anders Hviid1,3 3
-
- ¹ Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
6 ² Danish Cancer Institute. Cancer Epidemiology and Surveillance. Strandboulevard
- ² Danish Cancer Institute, Cancer Epidemiology and Surveillance, Strandboulevarden 49, 2100
7 Copenhagen, Denmark
-
- 8 ³ Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, Faculty of
- 9 Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, 9 Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen,
-
-
-

-
- 14 *Corresponding Author: Anna Laksaro: Anna Laksa
.
- $\frac{1}{2}$
-
- 17 Supplementary Materials: 8 supplementary sections, including 7 tables and 2 figures 7
-
-

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

20 Abstract

21 Simplified exposure classifications, such as ever exposed versus never exposed, are commonly used
22 in pharmacoepidemiology. However, this simplification may obscure complex use patterns relevant 21 23 to researchers. We introduce tame, an R package that offers a novel method for classifying 24 medication use patterns, capturing complexities such as timing, dose, and concurrent medication use 25 in real-world data. The core innovation of tame is its bespoke distance measure, which identifies 26 complex clusters in medication use and is highly adaptable, allowing customization based on the 27 Anatomical Therapeutic Chemical (ATC) Classification System, medication timing, and dose. By 28 prioritizing a robust distance measure, tame ensures accurate and meaningful clustering, enabling 29 researchers to uncover intricate patterns within their data. The package also includes tools for 30 visualizing and applying these clusters to new datasets. In a national Danish cohort study, tame 31 identified nuanced antidepressant use patterns before and during pregnancy, demonstrating its 32 capability to detect complex trends. tame is available on the Comprehensive R Archive Network at 33 [https://CRAN.R-project.org/package=tame] under an MIT license, with a development version on 34 GitHub at [https://github.com/Laksafoss/tame]. tame enhances medication use classification by 35 detecting complex interactions and offering insights into real-world medication usage, thus 36 improving stratification in epidemiological studies. 36 improving stratification in epidemiological studies.

37 Key Words

 $\frac{1}{2}$

38 39 enidemiology, medication trajectories, unsupervisory of $\frac{1}{2}$ package, $\frac{1}{2}$

 $\overline{2}$

It is made available under a CC-BY 4.0 International license.

40 INTRODUCTION

41 Developments in the field of machine learning, improvements in computing power, and the
42 increasing richness of data now make it feasible to conduct more nuanced analyses of medication 41 43 patterns. Central to these analyses is the construction of effective distance measures, which are 44 critical in determining the success of clustering methods. A number of recent studies have explored 45 data-driven approaches to exposure classification. For example, methods such as longitudinal k-46 means and latent class analysis have been applied to longitudinal medication data to classify 47 exposure trajectories $[1, 2, 3, 4]$, and these methods have been implemented in software such as the 48 R-packages km₁ [5, 6] and 1 cmm [7]. However, these existing methods exhibit significant limitations. 49 Primarily, they focus exclusively on drug exposure timing, which restricts their ability to account for 50 the full complexity of medication use patterns. By considering only the timing of drug exposure, 51 these methods overlook other critical factors such as dose intensity and the chemical and 52 therapeutic characteristics of the medications involved. This narrow focus limits their applicability, 53 particularly in scenarios where the interplay between different medications and their specific 54 attributes is crucial, such as in studies of drug safety and efficacy. Few developments have been 55 made to approaches which learn from both exposure timing and the chemical and therapeutic 56 characteristics of the medication(s) used [8]. To the authors' knowledge, no publicly available 57 software that learns from this combined information to identify real-world prescription drug use 58 software that learning that learning information to identify real-world prescription to identify real-world preserve in the combined information of the combined information drug use of the combined information drug use 58 patterns exists.

59 In this paper, we present a novel distance measure explicitly designed for the clustering of
50 medication use patterns, integrating exposure timing, dose intensity, and medication type based on 61 Anatomical Therapeutic Clustering (ATC) codes. This distance measure is the foundation of our 62 Anatomical Cluster Analysis (ACA) implemented in the foundation of function in our package tame. 62 – Hierarchical Cluster Analysis (HCA) implemented in the `medic()` function in our package tame.
63 – HCA is a general and highly adaptable approach to cluster analysis that allows for the clustering of 63 HCA is a general and highly adaptable approach to cluster analysis that allows for the clustering of
64 any data, provided that the user can specify the distance between any pair of observations. We \mathcal{L}_{max} any data, provided that the user can specify the distance between any pair of observations. We are distance between any pair of observations. We are distance between any pair of observations. We are distance

65 developed this distance measure specifically for the clustering of based on three of the central
66 characteristics of personal medication use: patterns of medication use by Anatomical Therapeutic 67 Clustering (ATC) code, exposure timing, and exposure dose. The distance measure allows for flexible 68 specification of the component parts $-$ ATC code, timing and dose $-$ and their relative importance. 69 The method avoids unwanted data reduction or oversimplification of information by defining the 70 distance measure on the person- and medication-specific level. Here, we apply the method to a 71 Danish nationwide cohort of pregnancies with at least one antidepressant used 0-24 weeks prior to 72 pregnancy onset in order to map Danish mothers' use of antidepressants leading up to- and during 72 pregnancy onset in order to map Danish mothers' use of antidepressants leading up to- and during 73 pregnancy.

74 IMPLEMENTATION

75 tame is implemented in R (R Development Core Team 2022) as a package and requires the following
76 R packages: dplvr(>1.1.0) fuzzvioin, magrittr, purrr, Rfast, rlang, stats, stringr, 76 R packages: dplyr (≥1.1.0), fuzzyjoin, magrittr, purrr, Rfast, rlang, stats, stringr,
77 tibble. tid∨r. tidvselect. Rcpp (≥ 1.0.8). A development version is also available on GitHub 77 tibble, tidyr, tidyselect, Rcpp (≥ 1.0.8). A development version is also available on GitHub
78 fhttps://github.com/Laksafoss/tamel and collaborators are welcome to fork or make pull requests. 78 The tame package provides methods for clustering medication data by ATC codes. dose and timing. 79 The tame package provides methods for clustering medication data by ATC codes, dose and timing,
80 The analysing and illustrating these clusters, and emploving these learned clusters to new data in a 80 analysing and illustrating these clusters, and employing these learned clusters to new data in a
81 similar format. These central functionalities are implemented in the functions `medic()`, 81 similar format. These central functionalities are implemented in the functions `medic()`,
82 `summarv()` and `emplov()` alongwithafewsupportingfunctions. The packagealsoincludes 82 `summary()`, and `employ()`, along with a few supporting functions. The package also includes
83 a simulated dataset for demonstrating the code. 83 a simulated dataset for demonstrating the code.

84 Clustering Analysis

85 Our medication clustering method, implemented in the `medic()` function, utilizes a novel
86 distance measure within an agglomerative hierarchical cluster analysis (HCA) framework. The 87 bespoke distance measure drives the clustering process by accurately quantifying the similarities $87.$ Bespoke distance measure drives the clustering process by accurately quantifying the similarities

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) . preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.06.24.24309427;](https://doi.org/10.1101/2024.06.24.24309427) this version posted September 12, 2024. The copyright holder for this

88 between any two individual-level medication use profiles. The quality and effectiveness of the
89 clustering hinge on this measure, making it the critical element of our methodology.

89 clustering hinge on this measure, making it the critical element of our methodology.

90 This distance measure is a composite that integrates multiple dimensions of medication information:
91 dose intensity, timing of medication and the ATC classification system. Figure 1 provides an overview 92 of this method, illustrating how the distance measure is constructed and applied within the 93 clustering process to group individuals based on their medication use patterns. 93 clustering process to group individuals based on their medication use patterns.

94 Difference in two individual-level medication profiles by dose intensity and timing of medication are
95 measured by a dose trajectory distance measure. This distance measure compares the medication 96 dose at each timepoint in the study and summarizes across time using the Minkowski distance. The 97 mathematics behind the method are available in S1, and a mathematical glossary is available in S2

97 mathematics behind the method are available in S1, and a mathematical glossary is available in S2 99 ATC code. The distance between two medications is found by identifying the deepest ATC code level 100 that is shared between the two medications. For example, sertraline N06AB06 and clomipramine 101 NO6AA04 are both antidepressants (NO6A) and are identical at ATC level 3, but sertraline NO6AB06 102 and oxycodone N02AA05 are only identical at ATC level 1, where they share the nervous system main 103 aroup (N). Thus, the distance between sertraline NO6ABO6 and clomipramine NO6AAO4 is smaller 104 than the distance between sertraline N06AB06 and oxycodone N02AA05. Note that if two 105 medications have the same ATC codes, their distance is 0, and they are considered to be the same 106 medication under this distance measure.

107 A wide range of parameters allow for the tuning of the dose trajectory distance measure, the ATC
108 distance measure, and their relative importance. This flexibility ensures that the distance measure 109 can be adapted to the specific context and research questions, preserving the complexity and 110 richness of the underlying data. Detailed explanations and discussions of these tuning parameters 111 and more can be found in S3.

It is made available under a CC-BY 4.0 International license.

-
- 112 While the method like all clustering methods is computationally intensive, these demands are
113 iustified by the need for accurate and meaningful clustering based on the detailed distance measure.
- 114 For a technical discussion on these aspects of the implementation, see S4. 114 For a technical discussion on these aspects of the implementation, see S4.
- 115 `medic()`**:**Identifying clusters
- 116 The `medic()` function is the central power house of the tame package. This function computes
117 the distances between all pairs of individuals, runs the hierarchical clustering algorithm, and returns
-
- 118 the clusters. See Figure 1 for a visual guide to the steps performed by the `medic()` function. 118 the clusters. See **Figure 1** for a visual guide to the steps performed by the `medic()` function,
119 tincluding how it calculates the composite distance measure and applies hierarchical clustering to
- 119 including how it calculates the composite distance measure and applies hierarchical clustering to
120 group individuals based on their medication use profiles.
- 120 group individuals based on their medication use profiles.

Code Chunk 1. Example of how to cluster medication use data using medic. The first example performs a simple clustering based solely on the ATC codes, grouping the complications dataset into 3 clusters. The second example performs a more detailed clustering that considers both ATC codes and the timing of exposure (from the first to third trimester). This returns clustering results with 3, 4, and 5 clusters (κ =3:5 κ), allowing for the exploration of different grouping structures in the data.

```
group<br># Load simulated data
data("complications") 
# A simple clustering based only on ATC 
clust \leftarrow medic(complications, id = id, atc = atc, k = 3)
# A clustering based on both ATC and exposure timing 
# returning clusterings with 3, 4, and 5 clusters 
clust \leftarrow medic(
    complications, 
   id = id\text{atc} = \text{atc} timing = first_trimester:third_trimester, 
   k = 3.5)
```
122 The function requires that the user provides a dataset where each row encodes personal medication
123 patterns of each medication. Thus, a person exposed to 3 medications has 3 rows in the data. In S5 124 examples of how data might be structured can be found. Columns in this dataset naming the person 125 identification variable, the medication ATC code variable, and, if available, one or more numerical 125 identification variable, the medication ATC code variable, and, if available, one or more numerical

It is made available under a CC-BY 4.0 International license.

-
- 127 variables encoding dose and/or exposure trajectory. The user specifies the assessment number(s) or
127 valuaters with the function input \mathcal{R} . Moreover, a number of function parameters can be used to 127 - clusters with the function input 'k'. Moreover, a number of function parameters can be used to
128 - tune the distance. A full discussion of these tuning parameters can be found in S3.
- 1288 tuning the distance. A full distance. A function of these tuning parameters can be found in S

- 130 `summary()`**:** Summarizing clusters
- 131 A wide range of cluster summarisation tools are implemented. Summary functions investigates
132 different aspects of the clustering characteristics and have a corresponding plotting method. The list
-
- 133 of summarisation approaches is given in the code documentation [9], and the latest version at time
- 134 of publication can be found in S7. As an example, Figure 2 has been made using these summary tools. $\frac{1}{2}$ of publication can be found in S7. As an example, Figure 2 has been made using these summary tools.

Code Chunk 2. Examples of how to make summaries of the clustering characteristics. Individual characteristics are summarized with functions like \in Cluster_frequency() \in

 δ `medication_frequency()`, `comedication_count()`, timing_trajectory()`, and `timing_atc_qroup()`. Multiple aspects can be summarized using `summary()`, either for `timing_atc_group()`. Multiple aspects can be summarized using `summary()`, either for
specific outputs or all characteristics. Generate a full summary plot for a specific cluster (e.g., `k
-------------------------------specific outputs or all characteristics. Generate a full summary plot for a specific cluster (e.g., `k
== 3`) using `plot_summary()`.To simplify or anonymize small groups, apply
`summary spec ()`hefere exective the summary $== 3$) using `plot_summary() To simplify or anonymize small groups, apply
Summary_crop() before creating the summary plot.

```
`summary_crop()` before creating the summary plot. 
# Summarizing individual aspect of the clustering 
clust |> cluster_frequency() 
clust |> medication_frequency() 
clust |> comedication_count() 
clust |> timing_trajectory() 
clust |> timing_atc_group() 
# Summarizing multiple aspects of the clustering 
clust |> summary(outputs = c("cluster_frequency", "timing_trajectory")) 
clust |> summary(outputs = "all")
# Making the full summary plot of the clustering with 3 clusters 
clust | plot_summary(only = k==3)
# To simplify or blind small groups apply the `summary_crop()` function 
clust |> 
   summary() |> 
  summary_crop(which = "medication_frequency", top_n = 3) \rightarrow plot_summary(only = k==5)
```
It is made available under a CC-BY 4.0 International license.

136 `employ()`**:** Applying Clusters to New Data

145 countries.
145 countries.
145 countries.

Code Chunk 3. Example of how to employ an already learned clustering to new data. The 'train' dataset (first 100 entries of complications) is clustered using the \hat{C} medic() \hat{C} function, with three clusters ($k = 3$). The resulting model ('clust') is then applied to the 'test' dataset (entries clusters ('k = 3'). The resulting model ('clust') is then applied to the 'test' dataset (entries
101–149) using the `employ()` function, allowing for the identification of similar medication
setters is a surable 101–149) using the `employ()` function, allowing for the identification of similar medication
patterns in new data.

```
patterns in new arm.<br># we have two distinct datasets 'train' and 'test'
train <- complications[1:100,] 
test <- complications[101:149,] 
# Cluster the medication data 'train' 
clust \leftarrow medic(train, id = id, atc = atc, k = 3)
# Employ the learned clusters to new data 'test' 
employ(clust, test)
```
147 Installation

148 The tame package is available on *The Comprehensive R Archive Network* (CRAN), and may be installed
149 The tame install and the ackages ("tame") in R >4.2. Additionally, development versions may be 149 by running `install.packages("tame")` in R ≥4.2. Additionally, development versions may be
150 available on github at https://github.com/Laksafoss/tame.

150 available on github at https://github.com/Laksafoss/tame.

It is made available under a CC-BY 4.0 International license.

132 OSE

153 To demonstrate the use and utility of tame, we apply the methodology to the medication use
154 immediately before- and during pregnancy using a cohort of Danish women with a history of 155 antidepressant use before pregnancy. We investigate how these medications are used in practice, 156 and how use is related to redeeming psycholeptics in the first year after pregnancy. Please note that 157 this study primarily serves as an example of how to use the package. 157 this study primarily serves as an example of how to use the package.

158 Ethics declaration

159 The Danish national registries used in this study are protected by the Danish Data Protection Act. No
160 informed consent nor approval from the Danish Research Ethics Committees were needed for this 161 study, since only national register data was used. By law, no ethics committee approval is required 162 for studies only using register-data. 162 for studies only using register-data.

163 Characterizing Antidepressant Use Before and During Pregnancy

164 We identified all live-born singleton births with a gestational age of at least 36 weeks between 1997
165 and 2016 in the Danish Medical Birth Registry [10]. Using the Danish National Prescription Registry, 164 166 the cohort was restricted to women who redeemed at least one antidepressant within the six 167 months before pregnancy. To conduct outcome analyses we also linked this cohort to a number of 168 registers on demographic, socioeconomic and healthcare information; for more on these variables 168 registers on demographic, socioeconomic and healthcare information; for more carriers candidates
169 registers on the anonymized individual-level data was accessed on Denmark Statistics' researcher 169 - see S6. The anonymized individual-level data was accessed on Denmark Statistics' researcher
170 - machines.on.December.12th.2023.

171 Assuming an exposure of WHO's defined daily dose each day, we estimated the time varying
172 antidepressant exposure of each individual from 24 weeks before pregnancy until gestational week 173 36 in the following medication groups: selective serotonin reuptake inhibitors (SSRI; ATC codes 174 starting with NO6AB), serotonin-norepinephrine reuptake inhibitors (SNRI; ATC codes starting with $174.$ starting with NO6AB), serotonin-norphrine reuptake inhibitors (SNRI; ATC codes starting with

9

170 machines on December 12th, 2023.

It is made available under a CC-BY 4.0 International license.

175 NO6AX), and others antidepressants (ATC codes starting with NO6AA, NO6AF or NO6AG). For each
176 individual and each day, antidepressant use was classified as exposed or unexposed (0/1). A 177 description and discussion of the tuning parameters chosen for this example may be found in S3. 178 Seven clusters were used to describe the data.

179 Figure 2 characterizes the clustering of antidepressant medication patterns learned from the data
180 Uning `medic()` and then illustrated with `plot_summary()` In the first column, the 181 characteristics of the entire population are illustrated, and the following 7 columns display the 182 characteristics of each cluster, highlighting distinct patterns within the data. Each row illustrates a 183 different characteristic: number of antidepressants used per person in the cluster, frequency of use 184 of the 5 most prevalent antidepressant ATC codes in the cluster, average cluster timing of all 185 antidepressant medications, SSRI use, SNRI use, other antidepressant use, respectively. 185 antidepressant medications, SSRI use, SNRI use, other antidepressant use, respectively.

186 For the entire study population (column 1), row 1 demonstrates that the majority (76%) of the
187 mothers take only one antidepressant in the study period, one-fifth are exposed to two 188 antidepressants, and even fewer (4%) are exposed to three or more antidepressants. In row 2, we 189 see that four out of five of the most used antidepressants are SSRIs. Rows 3 to 6 show the average 190 medication exposure trajectory among all medications (row 3), among SSRIs (row 4), among SNRIs 191 (row 5), and among other antidepressants (row 6). As we are considering a binary exposure in this 192 example, the average displayed may be interpreted at the percentage of pregnancies exposed at that 193 particular timepoint. The overall average (row 3) shows that at any given week before the 194 conception, at least half of the studied women are exposed to one or more antidepressants; then, 195 during the 12 first weeks of pregnancy, the antidepressant use drops. This pattern is consistent 196 across all three groups of antidepressants, but the level of use in any given week is different, with 197 SSRI usage being consistently more frequent than SNRI and other antidepressants (rows 3-6). We 198 further describe clusters II, III, and IV here, and all clusters in S8. 198 further describe clusters II, III, and IV here, and all clusters in S8.

It is made available under a CC-BY 4.0 International license.

199 Cluster II – "Sustained use of one SSRI": The second cluster, with 26% of pregnancies, is almost
200 exclusively SSRI single drug users. The pregnancies in this cluster has a high level of sustained SSRI 201 usage with at least 70% of pregnancies being exposed at any time point in the study period, and with 202 more than 90% of pregnancies being exposed in the weeks 0 to 13.

202 more than 90% of pregnancies being exposed in the weeks 0 to 13. 203 Cluster III – "Concomitant use of different types of antidepressants": The third largest cluster with
204 13% of pregnancies studied, is characterized by concomitant drug use of a mix of all 3 classes of 205 antidepressants. More than 88% of pregnancies are exposed to either SSRI or SNRI or both, while 206 only 18% of pregnancies are exposed to other antidepressants. The SSRI use frequency remains fairly 207 stable across the entire exposure period, as opposed to the SNRI use frequency which drops at the 207 stable across the entire exposure period, as opposed to the SNRI use frequency which drops at the SNRI use
208 start of the pregnancy. 208 start of the pregnancy.

209 Cluster IV – "Multiple SSRIs used": Cluster IV, which consists of 11% of pregnancies is characterized
210 by multiple drug use, with less than 3% using only one drug, almost 88% using 2 antidepressants, and 211 10% using 3 or more antidepressants. Unlike cluster III, where pregnancies are exposed to a mix of 212 different types of antidepressants, in this cluster, the exposure is multiple SSRIs. 212 different types of antidepressants, in this cluster, the exposure is multiple SSRIs.

213 Risk of redeeming psycholeptics within one year of birth according to medication cluster 214 membership

215 215 To give an example of how to use these learned medication clusters in further analysis, we apply
216 Them in an analysis of the adjusted cumulative incidence of adverse psychiatric post-partum 217 outcomes. In this example, redemption of psycholeptics (ATC group N05; anti-psychotics N05A, 218 anxiolytics NO5B, and hypnotics and sedatives NO5C) in the first year following birth is considered as 219 the outcome, as it serves as a concrete indicator of psychiatric distress and healthcare utilization, 220 directly impacting maternal and child well-being. 220 directly impacting maternal and child well-being.

221 We used stabilised inverse probability of treatment weighting. Weights were calculated as the
222 inverse odds of being assigned medication cluster I, III, IV, V, VI or VII versus medication cluster II 222 inverse odds of being assigned medication cluster I, III, IV, V, VI or VII versus medication cluster II

223 adjusted for confounders (see S8 for the full list) in a multinomial regression model. Cluster II was
224 - chosen as the reference cluster as it is a large cluster (26% or pregnancies) with a simple 225 interpretation (sustained use of one SSRI throughout the exposure period).

225 interpretation (sustained use of one SSRI throughout the exposure period). 226 Risk ratios and risk differences were then calculated at the 365-day mark. The results of the adjusted
227 All cumulative incidence analysis are shown in Figure 3a, and the estimated risk ratio and risk difference 228 by medication cluster are shown in Figure 3b. 228 by medication cluster are shown in Figure 3b.

229 From Figure 3b we see that three clusters have a significantly reduced risk of redeeming psycholeptic
230 Prescriptions within 1 year of birth as compared with cluster II, sustained exposure to one SSRI. 231 These three clusters are cluster I ("discontinuation of SSRI's"), cluster V ("discontinuation of SNRI's") 232 and cluster VI ("single use of antidepressants in the other antidepressants group"). Conversely, 233 cluster III ("multiple medication used across antidepressant groups") is significantly associated with 234 an increased risk of redeeming psycholeptics within 1 year of birth as compared with cluster II $\mathcal{O}(n^2)$ and increase risk of $\mathcal{O}(n^2)$ with cluster in the compared with cluster III year of $\mathcal{O}(n^2)$ and cluster III year of $\mathcal{O}(n^2)$ and cluster III year of $\mathcal{O}(n^2)$ and cluster III year of $\mathcal{O}(n^$

 $\sum_{i=1}^{n}$ 236 We can also observe from Figure 3b that neither cluster IV ("multiple SSRI's used"), nor cluster VII
237 ("sustained use of SNRI or other-antidepressants") where significantly associated with a higher risk of 238 redeeming psycholeptics as compared with cluster II ("sustained use of on SSRI"). All statistical 239 conclusions were supported on both the risk ratio and risk difference scale. 239 conclusions were supported on both the risk ratio and risk difference scale.

240 DISCUSSION

241 The tame package implements a novel data-driven learning method for understanding individual-
242 level medication patterns through hierarchical clustering and provides tools for illustrating and 243 characterising these clusters. The construction of a distance measure is the cornerstone of any 244 clustering method, as it dictates the method's ability to accurately group similar observations and 245 differentiate dissimilar ones. In machine learning, the quality of a distance measure directly impacts 246 the success of the model. Our novel distance measure, specifically tailored for medication data, $\frac{1}{4}$

It is made available under a CC-BY 4.0 International license.

247 uniquely incorporates the ATC code, exposure timing, and medication dosage, allowing researchers
248 to fine-tune the relative importance of these factors. This flexibility is crucial for ensuring that the 249 to clusters reflect the true nature of the data and the research objectives. Moreover, a method for 250 applying existing medication clusters to new medication pattern data has been developed. 250 applying existing medication clusters to new medication pattern data has been developed.

251 Here, we demonstrated how tame can help identify and narrow down complex trends of
252 antidepressant use before- and during pregnancy, using a national Danish cohort. In general, 253 clustering real-world medication data offers a valuable automated search method for detecting 254 potential safety signals or adverse drug interactions that may not have been previously suspected. 255 Unlike traditional approaches that rely on specific suspicions or hypotheses, clustering allows for an 256 exploratory analysis of medication patterns. For example, through clustering, researchers may 257 discover that a particular cluster, such as medications X and Y frequently taken together, is 258 associated with an elevated risk of adverse outcomes. This automated identification of medications 259 and medication combinations that pose potential risks can serve as an early warning system, 260 prompting further investigation into these specific medication combinations and their effects. 260 prompting further investigation into these specific medication combinations and their effects.

261 Moreover, real-world medication patterns captured through clustering analysis reflect the diverse
262 - medication usage habits of individuals outside controlled clinical trial settings. This real-world 263 complexity adds depth to our understanding of medication usage and its implications. Additionally, 264 these patterns can be leveraged for statistical adjustment or stratification in epidemiological studies. 265 By accounting for these real-world medication patterns, researchers can better control for 266 confounding factors and obtain more accurate estimates of treatment effects in epidemiological 267 studies and observational research.

268 Mhen using this method, specifying tuning parameters provides great customizability but require
269 decisions from the researcher. Thus, tuning the distance measure will still have to be done in 270 accordance with the understanding of the studied medication and the clinical setting. However, 270 according the understanding of the studied medication and the clinical setting. However, However,

It is made available under a CC-BY 4.0 International license.

271 methods for algorithmically optimizing the number of clusters and assisting in the choice of linkage
272 according to measures of goodness of fit is currently underway.

272 according to measures of goodness of fit is currently underway.

273 Naturally, clustering personal medication usage according to ATC codes is limited by the ATC
274 classification system itself. The ATC hierarchy classify according to main therapeutic use or 275 mechanism of action of the main active ingredient, and as such, encode the main indication of the 276 drug. However, many medications are used for multiple indications but will only be assigned one ATC 277 code according to the main indication. This can obscure the full spectrum of a medication's 278 applications. Moreover, an ATC group may be specified according to mechanism of action, resulting 279 in groups where the medications have diverse indications, complicating the interpretation of 280 clustering results. In addition, a chemical substance may be given more than one ATC code if it is 281 cused for two different therapeutic purposes. For a detailed introduction to the construction of 282 WHO's ATC classification system see [11]. Thus, as the ATC classification system classifies both 283 according to the therapeutic and the pharmacological aspects of a medication, so does the 284 classification method presented in this paper. Methods for extending the ATC distance measure to 285 allow for user defined exceptions or additions to the ATC classification system are in progress. This 286 extension will allow the user to give all medications with identical active ingredients a smaller 287 distance regardless of distance in the ATC hierarchy or make combination products more similar than 287 distance regardless of distance in the ATC hierarchy or make combination products more similar than
288 dhe ATC hierarchy suggests. $\frac{1}{2}$

289 In addition, a central feature of hierarchical clustering, and many other clustering methods, is that all
290 Observations are assigned a cluster. Thus, if the data contain many outliers, which in fact are not 291 comparable with other observation in the data, these will still be placed in clusters. Moreover, the 292 assignment to a cluster is done in a deterministic way, and the method does not provide uncertainty 293 estimates for this assignment. These features of clustering lead to less robustness to changes to the 294 estimates for the formulation. When using tame, the semploy () shortlon can be used to gain some insight into the semploy of control of the stock robustanes of control 294 294 study population. When using tame, the `employ()`function can be used to gain some insight into
295 the extent of this problem in a given dataset through cross validation type strategies. 295 the extent of this problem in a given dataset through cross validation type strategies.

It is made available under a CC-BY 4.0 International license.

296 Lastly, it should be noted that clustering methods can be very computationally time and RAM
297 demanding. This means that we may still be limited in our applications of this method to large 298 cohorts with wide medication use by our computational power. As discussed in S4, this central 299 limitation has informed multiple design aspects of the code itself, and computationally intensive 300 parts of the code are written in C++ or utilize code written in Fortran. This works to ensure a 301 relatively respectable computational time for our example with just over 33,000 antidepressant 302 exposed pregnancies of less than 10 minutes on a system with Intel(R) Xeon(R) Gold 6254 CPU @ 302 exposed pregnancies of less than 10 minutes on a system with Intel(R) Xeon(R) Gold 6254 CPU @

304 Conclusions

305 In summary, the tame package improves on classical approaches to understanding drug exposure by
306 In clustering complex, real-world use patterns which integrate information on timing, dose, and type of 307 medication. Here, we described an application of how we have used this method to understand 308 antidepressant use up to and during pregnancy, and then analyse how these learned clusters were 309 associated with the use of psycholeptics in the first year following birth. In the future, the method 310 may be used to understand other patterns of prescription drug use and optimize drug safety 311 surveillance through data driven learning. 311 surveillance through data driven learning.

312 ACKNOWLEDGMENTS

313 Authors thank Kim Daniel Jakobsen for his invaluable assistance in the development of the
314 methodology employed in this study. We would also like to thank Elisabeth O'Regan for her 315 meticulous attention to detail in formatting and refining the English language of this manuscript. 315 meticulous attention to detail in formatting and refining the English language of this manuscript.

medRxiv preprint doi: [https://doi.org/10.1101/2024.06.24.24309427;](https://doi.org/10.1101/2024.06.24.24309427) this version posted September 12, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grant

It is made available under a CC-BY 4.0 International license.

316 AUTHOR CONTRIBUTIONS

- 317
- 317 Conceptualising R package functionalities: A.D.L. and J.W. Code development and documentation:
318 A.D.L. Code testing: A.D.L. Study concept and design: A.D.L., J.W. and A.H.. Data analysis: A.D.L.
- 319 Manuscript writing: A.D.L. Critical review: A.D.L., A.H. and J.W. Funding: A.H. 319 Manuscript writing: A.D.L. Critical review: A.D.L., A.H. and J.W. Funding: A.H.

320 DATA AVAILABILITY STATEMENT

- 321 321 Data cannot be shared publicly because of data privacy regulations in Denmark. Applications for data
322 access should be submitted to Research Services at the Danish Health Data Authority.
- 322 access should be submitted to Research Services at the Danish Health Data Authority.

$\frac{323}{1000}$

- 324 324 This work was supported by a grant from the Independent Research Fund Denmark – "Exploring new
325 ways of classifying medication use in pregnancy for better observational research" (9039-00055B)
- 325 ways of classifying medication use in pregnancy for better observational research $(9039-0055B)$

326 COMPETING INTERESTS STATMENT

327 The authors declare no competing interests.

328 **Figure 1.** Overview of the `medic()` function for quantifying and clustering individual-level
329 medication profiles. The method calculates the similarity between medications using ATC codes and 330 dosing trajectories, combining these into a comprehensive distance measure that accounts for both 331 dose intensity and timing. Hierarchical clustering is then applied to group individuals based on these 332 medication use patterns, revealing similarities in their profiles. 332 medication use patterns, revealing similarities in their profiles.

334 Figure 2. Characteristics of medication use clusters in a cohort of 33,655 Danish pregnant women
335 b with at least one antidepressant prescription within the six months before pregnancy. The figure 336 with at least one and the sixth of the six monotoness of the six monotoness is monotoned in the finedic Ω . 336 illustrates the clustering of these medication patterns, learned from the data using the `medic()`
337 function and visualized with `nlot_summarv()`.The first column represents the entire population. 337 function and visualized with `plot_summary()`. The first column represents the entire population,
338 while the subsequent seven columns depict the characteristics of each cluster, revealing distinct 339 patterns. Each row provides a different characteristic: the first row illustrates the number of 340 antidepressants used, the second row illustrates the 5 most prevalent antidepressant ATC codes, and 341 the remaining 4 rows illustrate the average antidepressant exposure timing by anti-depressive type. 341 the remaining 4 rows illustrate the average antidepressant exposure timing by anti-depressive type.

343 Fi**gure 3.** Adjusted* risk of redeeming psycholeptics in the first year following birth according to
344 Finedication cluster membership. 344 medication cluster membership.

345 (A) Adjusted cumulative incidence of redeeming psycholeptics in the first year following birth
346 according to medication cluster membership. (B) Adjusted risk ratio and risk difference per 100 347 pregnancies of redeeming psycholeptics one year after birth according to medication cluster 347 pregnancies of redeeming psycholeptics one year after birth according to medication cluster 348 membership.

349 * Both absolute (A) and relative (B) risks were adjusted for maternal age (<25, 25-29, 30-34, ≥35),
350 parity (0, 1, 2, ≥3), BMI (<18.5, 18.5-25, 25-30, 30-35, >35), smoking status (non-smoker, stopped 351 smoking or smoker), family structure (married, single, or living with partner), maternal employment $\frac{3}{5}$ smooth or smooth or living with partner $\frac{1}{5}$ single, or living with partner $\frac{1}{5}$

medRxiv preprint doi: [https://doi.org/10.1101/2024.06.24.24309427;](https://doi.org/10.1101/2024.06.24.24309427) this version posted September 12, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grant

It is made available under a CC-BY 4.0 International license.

352 status (employed, employed in a management position, self-employed, or unemployed and receiving
353 public assistance), maternal level of education (primary, secondary, postsecondary, or vocational 354 school), location of residence in Denmark (capital region, central region, northern region, Zealand, or 355 southern region), disposable household income (quartile 1, 2, 3, or 4), and maternal country of origin 356 (Denmark, Europe (without Denmark), or other), history of psychiatric hospitalizations, history of 357 self-harm and Charlson comordibity score ≥1. $\frac{1}{3}$

It is made available under a CC-BY 4.0 International license.

REFERENCES

- [1] C. Hurault-Delarue, C. Chouquet, N. Savy, I. Lacroix, A.-B. Beau, J.-L. Montastruc and C. Damase-Michel, "How to take into account exposure to drugs over time in pharmacoepidemiology Michel, "Michel, "Michel, "How to take into a control of the into a
Michel, "How to the pharmacoepidemiology and Drug Safety, vol. 25, no. 7, pp. 770studies of pregnant women?," *Pharmacoepidemiology and Drug Safety,* vol. 25, no. 7, pp. 770-
777. 2016. 77
777, 2016.
2017.
- [2] M. E. Wood, A. Lupattelli, K. Palmsten, G. Bandoli, C. Hurault-Delarue, C. Damase-Michel, C. D. Exposures in Pharmacoepidemiologic Studies in Pregnancy," Epidemiologic Reviews, vol. 43, no. Exposures in Pharmacoepidemiologic Studies in Pregnancy," Epidemiologic Reviews, vol. 43, no. $\frac{1}{2}$
- [3] L. S. Lemon, L. M. Bodnar, W. Garrard, R. Venkataramanan, R. W. Platt, O. C. Marroquin and S. N. Caritis, "Ondansed an accuration use in the first trimester of pregnancy and the risk of neonatal ventricular
Septal defect." International Journal of Epidemioloav. vol. 49. no. 2. pp. 648-656. 2019. septal defect," International Journal of Epidemiology, vol. 49, no. 2, pp. 648-656, 2019.
- $[4]$ D. Steinley, "K-means clustering: A half-century synthesis," British Journal of Mathematical and
Statistical Psychology, vol. 59, no. 1, np. 1-34, 2006. Statistical Psychology, vol. 59, no. 1, pp. 1-34, 2006.
- $[5]$ C. General, μ and consider and C. Arnaud, "kml and kmlsd: R Packages to Cluster R μ Packages to Cluster R μ Longitudinal Data," Journal of Statistical Software, vol. 65, no. 4, pp. 1-34, 2015.
- [6] C. Genolini, B. Falissard and P. Kiener, "R package version 2.4.6," 2023. [Online]. Available:
https://CRAN.R-project.org/package=kml. h_{ref} is a multiple project.org/package=kml.
- er and the constant of the Lima
Classes and Latent Processes: The R Package Icmm." Journal of Statistical Software, vol. 78, no. Classes and Latent Processes: The R Package lcmm," Journal of Statistical Software, vol. 78, no. 2, p. 1–56, 2017.
- [8] S. Salvatore, D. Domanska, M. Wood, H. Nordeng and S. Geir Kjetil, "Complex patterns of

 $\begin{array}{ccccc} \texttt{c} & \texttt{c} & \texttt{c} & \texttt{c} & \texttt{c} \ \texttt{c} & \texttt{c} & \texttt{c} & \texttt{c} & \texttt{c} \ \texttt{c} & \texttt{c} & \texttt{c} & \texttt{c} & \texttt{c} \ \texttt{c} & \texttt{c} & \texttt{c} & \texttt{c} & \texttt{c} & \texttt{c} \ \texttt{c} & \texttt{c} & \texttt{c} & \texttt{c} & \texttt{c} & \texttt{c} \ \texttt{c} & \texttt{c} & \texttt{c} & \text$ pregnancy," PLOS ONE, vol. 12, no. 12, pp. 1-11, 2017.

- [9] A. Laksafoss, tame: Timing, Anatomical, Therapeutic and Chemical Based Medication Clustering,
- [10] M. Bliddal, A. Broe, A. Pottegård, J. Olsen og J. Langhoff-Roos, »The Danish Medical Birth
Register,« European Journal of Epidemiology, årg. 33, nr. 1, pp. 27-36, January 2018. Register,« European Journal of Epidemiology, årg. 33, nr. 1, pp. 27-36, January 2018.
- [11] Health, Norwegian Institute of Public, Last updated: 2022-11-10. [Online]. Available:
https://www.whocc.no/atc/structure and principles/. [Senest hentet eller vist den 2023-12https://www.whocc.no/atc/structure_and_principles/. [Senest hentet eller vist den 2023-12- 19]].
- [12] N. T. H. Trinh, T. Munk-Olsen, N. R. Wray, V. Bergink, H. M. E. Nordeng, A. Lupattelli and X. Liu, gant of Anti-depressed of Anti-depth
Timing of Anti-depressed online March 08, 2023.
During Pregnancy and Norway and Psychiatry. Published online March 08, 2023. Outcomes in Denmark and Norway," JAMA Psychiatry, Published online March 08, 2023.
- [13] A. Pottegård, S. A. J. Schmidt, H. Wallach-Kildemoes, H. T. Sørensen, J. Hallas and M. Schmidt,

"Data Resource Profile: The Danish National Prescription Registry," International Journal of Data Resource Profile: The Danish National Prescription Registry, "*International Journal of*
Foidemiology, vol. 46, no. 3, pp. 798-798f, 2017. Epidemiology, vol. 46, no. 3, pp. 798-798f, 2017.
- Figure Shanny A. Broe, A. Pottegård, A. Potten and A. Banghorf A. P., A. Pottegård, M. Langhorff-Roos, 27-36.
Register." *European Journal of Epidemioloav.* vol. 33. no. 1. pp. 27-36. January 2018. Register," European Journal of Epidemiology, vol. 33, no. 1, pp. 27-36, January 2018.

Input Data

The `medic() `function processes individual-level medication data, where each row represents a unique medication exposure for a person. The function requires ATC codes and allows for inclusion of dose intensity and timing information. The example dataset depicted in this figure shows Individuals A, B, C, D, and E with varying numbers of medications, each represented with their ATC codes and dose trajectories.

ATC Distance Measure

The similarity between two medication ATC codes is quantified using the deepest ATC code level shared between the two medications. Distances are encoded as θ_0 , θ_1 , θ_2 , θ_3 , θ_4 , or $\theta_5 = 0$, depending on which ATC level the medications match. For instance, medications with identical first-level ATC codes have a distance θ_1 , while those matching at the deeper level 4 have a smaller distance θ_4 . These θ values are tunable by the user to better reflect the specific context of the study.

Dose & Timing Distance Measure

The similarity between two medication dose and timing trajectories is computed using the Minkowski distance. This measure compares the dose intensity at each time point and summarizes the differences across the entire exposure period. It ensures that medications with similar dosing patterns are recognized as more alike, even if their exact doses differ.

The Distance Measure

The comprehensive distance between two individual-level medication profiles is calculated by integrating both the ATC distance and the dose and timing distance. The formula captures the balance between these two components, allowing customization through the parameters α, β and γ to weigh the relative importance of ATC codes versus dose trajectories. In this example we have used the "average distance measure" formula, which is one of two formulas we have developed for tame.

$$
d\left(\frac{\otimes}{\alpha},\frac{\otimes}{\alpha}\right) = \frac{1}{(n\cdot m)^{\alpha}} \sum \left(\left(1 - \left[ATC\;Distance\right]\right) \left(1 - \gamma \left[Does\;&\;Timing\;Distance\right]\right) - 1 \right)^{\beta}
$$

medRxiv preprint doi: [https://doi.org/10.1101/2024.06.24.24309427;](https://doi.org/10.1101/2024.06.24.24309427) this version posted September 12, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grant

It is made available under a $CC-BY 4.0$ International line

Hierarchical Clustering

The `medic() `function uses agglomerative hierarchical clustering to group individuals based on the distances between their medication use patterns. The clusters reveal similarities in medication profiles, where individuals within the same cluster share closer ATC and dosing trajectory patterns. In this example Individuals A, C, and E form Cluster I, and Individuals B and D form Cluster II, reflecting their medication use similarities.

B

